Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KITAIbodies
- Development stage
- Preclinical
- Lead developer
- Mesenkia Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
KITAIbodies is a preclinical-stage bispecific antibody candidate developed by Mesenkia Therapeutics, specifically designed for the treatment of glioblastoma. The molecule utilizes a modular nanobody or single-domain antibody format derived from alpaca antibodies. Its primary mechanism of action involves targeting the Herpesvirus entry mediator (HVEM, also known as TNFRSF14) to disrupt two critical signaling pathways: the APRIL-HVEM-NFκB axis, which drives the growth of glioblastoma cancer stem cells, and the BTLA-HVEM axis, which facilitates immune suppression within the tumor microenvironment. In August 2026, Mesenkia announced a research collaboration with BioArctic AB to integrate KITAIbodies with BioArctic's BrainTransporter™ technology, aimed at improving the delivery of the therapeutic across the blood-brain barrier.
- Brand names
- KITAIbodies
- Other names
- KITAIbodies bispecific antibodyKITAIbodies lead candidateKITAIbodies bispecific drug candidate
02
Targets
TMEFF2
Beyond the preview
Go deeper on KITAIbodies.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KITAIbodies.